Our long term vision and goals

Replacing Animal Testing Through Technological Convergence

Experience a new age of drug testing

We are convinced that the technological convergence of Microfluidic Organ-On-Chip, Multi-omics, the most advanced imaging techniques and artificial intelligence will allow to better predict drugs effects on the human body and bring the possibility to replace animal testing

Most experiments on animals are not relevant to human health. This leads to very high failure rates (<95%) of drugs tested on current preclinical animal models (first evaluation of a drug candidate before clinical trial or administration to humans).

Our mission is to develop a technological platform combining microfluidic technology, artificial intelligence, and the most advanced imaging techniques allowing the scientific paradigm shift from animal to 3D In vitro toxicology and efficacy prediction.

This platform allows us to validate at an early stage (before clinical trials) the safety and efficacy of the drug under development.

Reliable and early predictions allow us to focus human resources and financial investments towards the best drug candidates. The reduction of the development cost of each new drug will permit on the investment in the drugs better able to treat rare and chronic diseases, cancer, bacterial resistance and viral pandemics.
Besides, this platform is an alternative to the animal model, which is still widely used because it is regulated, although ineffective.

Our Vision

To reduce and replace animal testing to predict drugs effects on human body, we are convinced that we can reach the full potential of drug prediction by combining Artificial Intelligence, Microfluidic instruments, Multi Omic Sensors and High-resolution live Imaging.

Our Mission

Our mission is to develop an Organ-On-Chip platform that will provide massive and high-quality biological data coming from Multi-Omic analysis & the most advanced imaging techniques. This approach has the potential to become the next standard in drug development and replace animal experimentation.

Our Unique Approach

We convert any commercial multiwell plate into a standard in vitro 3D cell culture plate by adding our microfluidic perfusion lid, to culture any tissue, organs, physiopathologic and pathologic.

Meet the team

Giulia Antonioli Financial & Administrative Manager

Pierre Gaudriault, PhD Scientific & Preclinical Studies Manager
Mathilde Cadoux, PhD Immunologist Project Manager

Antoni Homs Corbera, PhD Chief Scientific Officer

Chloe Porcier Human Resources Manager

Jeremy Cramer, PhD Co-Founder & CEO

Priyanka Fernandes, PhD Immunologist Project Manager

Jean-Robin Peiteado Mechatronics Project Manager

Alberto Ortega Production, Industrialization & After-sales Services Manager
Dana Hassan AI PhD student

Dario Fassini, PhD Head of Preclinical Model Development
Hang Pham Lead Acquisition & Marketing Manager
Harry Dawson, PhD Scientific Project Manager

Hadhemi Mejrl Biotechnology Engineer and Lab Manager
Mehdi Faraj Production, Logistic & Purchasing Assistant
Valérie Berthelon Office Manager
Naël Mokrane Fullstack Web Developer Apprentice
Jegash Srikandarajah Production & Quality Control Engineer Apprentice

Values & Cultures

We are all passionate about improving human health and animal wellfare.

To succeed in our mission,  we have also built a strong culture based on 3 major axes :

  • Good sense of humor
  • Cooperation
  • Surpassing yourself



Surpassing yourself

Milestones & Highlights

Cherry Biotech - Our story - Milestones

They Trust Us

speak with our expert

Speak directly with one of our experts to see how our products and services can support your research project
Scroll to Top